LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Akciju saraksts・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Slēgts

SektorsVeselības aprūpe

164.29 5.25

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

156.08

Max

164.53

Galvenie mērījumi
By Trading Economics
Ienākumi	262M -15M
Pārdošana	1.6M 996M
EPS	-0.3
Peļņas marža	-1.486
Darbinieki	18,300
EBITDA	-11M 187M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+31.04% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-781M 7.7B
Iepriekšējā atvēršanas cena	159.04
Iepriekšējā slēgšanas cena	164.29

Ziņu noskaņojums

By Acuity

94%

15 / 344 Rangs Healthcare

Charles River Laboratories International Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 27. maijs 21:33 UTC

Peļņas

Correction to Salesforce 1Q Sales, Profit Rise Article

2026. g. 27. maijs 21:00 UTC

Iegādes, apvienošanās, pārņemšana

HCA Healthcare Agrees to Buy The College of Health Care Professions

2026. g. 27. maijs 20:18 UTC

Peļņas

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

2026. g. 27. maijs 23:49 UTC

Tirgus saruna

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

2026. g. 27. maijs 23:39 UTC

Tirgus saruna

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

2026. g. 27. maijs 23:34 UTC

Tirgus saruna

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

2026. g. 27. maijs 23:34 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 27. maijs 23:08 UTC

Tirgus saruna

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

2026. g. 27. maijs 22:21 UTC

Tirgus saruna

Salesforce Lays Out AI Monetization Strategy -- Market Talk

2026. g. 27. maijs 21:29 UTC

Karstas akcijas

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

2026. g. 27. maijs 21:08 UTC

Peļņas

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

2026. g. 27. maijs 21:02 UTC

Peļņas

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

2026. g. 27. maijs 20:59 UTC

Iegādes, apvienošanās, pārņemšana

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

2026. g. 27. maijs 20:55 UTC

Peļņas

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

2026. g. 27. maijs 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 27. maijs 20:48 UTC

Peļņas

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

2026. g. 27. maijs 20:45 UTC

Peļņas

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

2026. g. 27. maijs 20:34 UTC

Iegādes, apvienošanās, pārņemšana

Webster Financial Stockholders Approve Sale to Banco Santander

2026. g. 27. maijs 20:32 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

2026. g. 27. maijs 20:32 UTC

Iegādes, apvienošanās, pārņemšana

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

2026. g. 27. maijs 20:32 UTC

Iegādes, apvienošanās, pārņemšana

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

2026. g. 27. maijs 20:30 UTC

Peļņas

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

2026. g. 27. maijs 20:30 UTC

Iegādes, apvienošanās, pārņemšana

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

2026. g. 27. maijs 20:22 UTC

Peļņas

Salesforce Stock Slides on Mixed Results -- Barrons.com

2026. g. 27. maijs 20:16 UTC

Peļņas

Salesforce Stock Slides on Mixed Results -- Barrons.com

2026. g. 27. maijs 20:13 UTC

Peļņas

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

2026. g. 27. maijs 20:13 UTC

Peļņas

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

2026. g. 27. maijs 20:13 UTC

Peļņas

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

2026. g. 27. maijs 20:12 UTC

Peļņas

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

2026. g. 27. maijs 20:12 UTC

Peļņas

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Salīdzinājums

Cenas izmaiņa

Charles River Laboratories International Inc Prognoze

Cenas mērķis

By TipRanks

31.04% augšup

Prognoze 12 mēnešiem

Vidējais 205.38 USD 31.04%

Augstākais 235 USD

Zemākais 160 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

10 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 10 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

15 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.